| Suspended | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC NCT05403723 | University of Maryland, Baltimore | Phase 1 |
| Not Yet Recruiting | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC NCT07459634 | Jazz Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cance NCT07509034 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previ NCT07328490 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Ti NCT07502300 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC NCT07388875 | China Medical University, China | Phase 2 |
| Recruiting | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER NCT07107490 | Chugai Pharmaceutical | Phase 1 |
| Recruiting | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (D NCT07037758 | Amgen | Phase 1 |
| Not Yet Recruiting | Prospective Observational Study on ES-SCLC NCT07173946 | Peking Union Medical College Hospital | — |
| Recruiting | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etopo NCT07005128 | Amgen | Phase 3 |
| Not Yet Recruiting | Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell L NCT07061535 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 | Peking Union Medical College Hospital | Phase 4 |
| Recruiting | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carb NCT06897579 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Com NCT06646276 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment o NCT07244016 | Henan Cancer Hospital | — |
| Recruiting | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With U NCT06712355 | BioNTech SE | Phase 3 |
| Not Yet Recruiting | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive- NCT06614621 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer NCT06807632 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Not Yet Recruiting | Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of NCT06732258 | Sichuan University | Phase 1 |
| Not Yet Recruiting | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) NCT06719336 | Anhui Shi, MD | Phase 3 |
| Not Yet Recruiting | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC NCT06597513 | Zhou Chengzhi | Phase 1 / Phase 2 |
| Recruiting | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) NCT06598306 | Amgen | Phase 1 |
| Withdrawn | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer NCT06427369 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung NCT06554535 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Not Yet Recruiting | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line NCT06478043 | Zhejiang Cancer Hospital | Phase 2 |
| Active Not Recruiting | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Pri NCT06502977 | Amgen | Phase 2 |
| Recruiting | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage NCT05588388 | Kamya Sankar | Phase 2 |
| Active Not Recruiting | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Canc NCT06449209 | BioNTech SE | Phase 2 |
| Not Yet Recruiting | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC NCT06497530 | Guangzhou Institute of Respiratory Disease | Phase 2 |
| Recruiting | Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC NCT06536868 | Second Hospital of Shanxi Medical University | Phase 2 |
| Recruiting | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maint NCT06362252 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Completed | MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy NCT07489339 | Shanxi Province Cancer Hospital | N/A |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer NCT06437509 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lun NCT06211036 | Amgen | Phase 3 |
| Recruiting | Radiotherapy to All Residual Lesions After Chemoimmunotherapy NCT06479473 | Anhui Provincial Hospital | Phase 1 / Phase 2 |
| Recruiting | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive NCT06217757 | Sichuan University | Phase 1 / Phase 2 |
| Active Not Recruiting | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer NCT06227546 | Georgetown University | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-trea NCT06332950 | Baohui Han | Phase 1 / Phase 2 |
| Unknown | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Sta NCT06323265 | Hebei Medical University Fourth Hospital | — |
| Not Yet Recruiting | A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. NCT06306560 | Harbin Medical University | Phase 2 |
| Terminated | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Ca NCT06016270 | STCube, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Pre NCT06008353 | AstraZeneca | — |
| Unknown | Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stag NCT05991180 | Hunan Province Tumor Hospital | — |
| Unknown | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radi NCT06586697 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan NCT05874401 | Pharmacosmos A/S | Phase 4 |
| Recruiting | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-S NCT06223711 | Universität des Saarlandes | Phase 2 |
| Withdrawn | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer NCT05572476 | Institut Bergonié | Phase 2 |
| Suspended | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer NCT05903092 | Hirva Mamdani | Phase 2 |
| Unknown | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer NCT05975944 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 / Phase 2 |
| Unknown | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy NCT05896059 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 | Sichuan University | Phase 2 |
| Unknown | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC NCT05668767 | Beijing Chest Hospital | Phase 2 |
| Active Not Recruiting | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES- NCT05468489 | Shanghai Henlius Biotech | Phase 3 |
| Recruiting | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer NCT04790253 | European Organisation for Research and Treatment of Cancer - EORTC | N/A |
| Completed | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer NCT05509699 | Hutchison Medipharma Limited | Phase 2 |
| Active Not Recruiting | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensi NCT05361395 | Amgen | Phase 1 |
| Recruiting | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) NCT05068232 | University of Chicago | Phase 2 |
| Not Yet Recruiting | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell L NCT05484583 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 2 |
| Active Not Recruiting | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide NCT05142696 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell NCT05309629 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung C NCT04397003 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) NCT05280470 | Daiichi Sankyo | Phase 2 |
| Unknown | Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC NCT05092412 | You Lu | Phase 2 |
| Active Not Recruiting | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy NCT05796089 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Completed | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With E NCT04774380 | AstraZeneca | Phase 3 |
| Completed | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors NCT05002868 | Rhizen Pharmaceuticals SA | Phase 1 |
| Unknown | To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. NCT04985851 | Shanghai Chest Hospital | N/A |
| Completed | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemot NCT05071703 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC NCT04878016 | Lee's Pharmaceutical Limited | Phase 3 |
| Completed | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Canc NCT04894591 | Jazz Pharmaceuticals | — |
| Unknown | Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer NCT04933175 | Liu Zhenhua | Phase 2 |
| Completed | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patien NCT04902885 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage S NCT04699838 | Muhammad Furqan | Phase 2 |
| Unknown | a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung C NCT04790539 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Unknown | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer NCT05761977 | Hellenic Cooperative Oncology Group | — |
| Active Not Recruiting | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer NCT04487756 | Instituto Oncológico Dr Rosell | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Exten NCT04702880 | Bristol-Myers Squibb | Phase 2 |
| Unknown | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC NCT05001412 | Zhou Chengzhi | Phase 1 |
| Unknown | Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer NCT04947774 | Chinese Academy of Medical Sciences | — |
| Terminated | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer NCT04373369 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC NCT04562337 | Shandong Cancer Hospital and Institute | Phase 2 |
| Unknown | Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC NCT04663438 | Peking Union Medical College Hospital | — |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 NCT04101357 | BioNTech SE | Phase 1 / Phase 2 |
| Completed | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Sma NCT04636762 | Second Xiangya Hospital of Central South University | Phase 2 |
| Unknown | A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer NCT04404543 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer NCT04346914 | Lee's Pharmaceutical Limited | Phase 1 |
| Unknown | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Can NCT04213937 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Pat NCT04254471 | Haihe Biopharma Co., Ltd. | Phase 2 / Phase 3 |
| Completed | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC NCT04063163 | Shanghai Henlius Biotech | Phase 3 |
| Unknown | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemoth NCT04056949 | Junling Li | Phase 2 |
| Completed | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Ad NCT03911219 | iOMEDICO AG | — |
| Completed | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer NCT03913455 | Shadia Jalal, MD | Phase 2 |
| Unknown | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer NCT03971214 | Chinese Academy of Medical Sciences | Phase 1 |
| Completed | Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer NCT05055947 | Hunan Province Tumor Hospital | — |
| Unknown | Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer NCT03841136 | Fudan University | Phase 2 |
| Completed | Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer NCT05055999 | Hunan Province Tumor Hospital | — |
| Unknown | Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer NCT04675697 | Xiangya Hospital of Central South University | Phase 2 |
| Unknown | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (E NCT03711305 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer NCT03781869 | Third Military Medical University | Phase 2 |
| Terminated | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With NCT03516084 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 |
| Completed | SGI-110 Plus Durvalumab/Tremelimumab in SCLC NCT03085849 | Catherine Shu | Phase 1 |
| Unknown | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line C NCT03135977 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Completed | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer NCT03043599 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Unknown | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeu NCT02972320 | Yunpeng Liu | Phase 2 |
| Unknown | Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer NCT02772107 | Chinese PLA General Hospital | Phase 2 / Phase 3 |
| Completed | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell L NCT02194049 | University of California, Davis | Phase 1 |
| Terminated | Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cel NCT02011087 | Wake Forest University Health Sciences | N/A |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Completed | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive St NCT01987232 | Amgen | Phase 1 / Phase 2 |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Terminated | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent NCT01803269 | University of Chicago | Phase 2 |
| Withdrawn | Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carbopla NCT01563601 | Cephalon | Phase 3 |
| Unknown | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With NCT01555710 | Alaunos Therapeutics | Phase 3 |
| Completed | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cance NCT01331525 | University Hospital Southampton NHS Foundation Trust | Phase 2 |
| Withdrawn | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body NCT01325753 | Wake Forest University Health Sciences | N/A |
| Completed | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer NCT02323737 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cance NCT01076504 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer NCT00828139 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer NCT00791154 | NantCell, Inc. | Phase 1 / Phase 2 |
| Completed | R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer NCT00773955 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung C NCT00682981 | Gemin X | Phase 1 / Phase 2 |
| Completed | AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer NCT00528645 | National Cancer Institute (NCI) | Phase 2 |
| Completed | R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extens NCT00544596 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC NCT00616109 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer NCT00470054 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cel NCT00079040 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer NCT00182689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell NCT00098956 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer NCT00118235 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung NCT00057837 | Eastern Cooperative Oncology Group | Phase 2 |
| Terminated | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or NCT00088933 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Ce NCT00084487 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Ce NCT00042978 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer NCT00028028 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small NCT00017251 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |
| Temporarily Not Available | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer NCT07535359 | Daiichi Sankyo | — |